IL300086A - Treatment of B-cell malignancies - Google Patents
Treatment of B-cell malignanciesInfo
- Publication number
- IL300086A IL300086A IL300086A IL30008623A IL300086A IL 300086 A IL300086 A IL 300086A IL 300086 A IL300086 A IL 300086A IL 30008623 A IL30008623 A IL 30008623A IL 300086 A IL300086 A IL 300086A
- Authority
- IL
- Israel
- Prior art keywords
- binding fragment
- baffr antibody
- use according
- administered
- lymphoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Seeds, Soups, And Other Foods (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060786P | 2020-08-04 | 2020-08-04 | |
| US202063114363P | 2020-11-16 | 2020-11-16 | |
| US202163147507P | 2021-02-09 | 2021-02-09 | |
| PCT/US2021/044113 WO2022031567A1 (en) | 2020-08-04 | 2021-08-02 | Treatment of b cell malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300086A true IL300086A (en) | 2023-03-01 |
Family
ID=77448106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300086A IL300086A (en) | 2020-08-04 | 2021-08-02 | Treatment of B-cell malignancies |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230279132A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4192869A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7834711B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230042594A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116133687A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021320129B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3190678A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL300086A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202221033A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022031567A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83458C2 (uk) * | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| AU2009272771B2 (en) | 2008-07-17 | 2012-09-20 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US11136405B2 (en) * | 2016-06-06 | 2021-10-05 | Board Of Regents, The Unviersity Of Texas System | BAFF-R antibodies and uses thereof |
| CA3160207A1 (en) * | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjogren's syndrome |
-
2021
- 2021-08-02 JP JP2023507275A patent/JP7834711B2/ja active Active
- 2021-08-02 AU AU2021320129A patent/AU2021320129B2/en active Active
- 2021-08-02 KR KR1020237007141A patent/KR20230042594A/ko active Pending
- 2021-08-02 CA CA3190678A patent/CA3190678A1/en active Pending
- 2021-08-02 WO PCT/US2021/044113 patent/WO2022031567A1/en not_active Ceased
- 2021-08-02 CN CN202180062994.8A patent/CN116133687A/zh active Pending
- 2021-08-02 EP EP21758931.6A patent/EP4192869A1/en active Pending
- 2021-08-02 IL IL300086A patent/IL300086A/en unknown
- 2021-08-02 TW TW110128346A patent/TW202221033A/zh unknown
- 2021-08-04 US US18/019,469 patent/US20230279132A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023536596A (ja) | 2023-08-28 |
| AU2021320129B2 (en) | 2025-12-18 |
| KR20230042594A (ko) | 2023-03-28 |
| JP7834711B2 (ja) | 2026-03-24 |
| WO2022031567A1 (en) | 2022-02-10 |
| US20230279132A1 (en) | 2023-09-07 |
| AU2021320129A1 (en) | 2023-03-16 |
| CA3190678A1 (en) | 2022-02-10 |
| TW202221033A (zh) | 2022-06-01 |
| CN116133687A (zh) | 2023-05-16 |
| EP4192869A1 (en) | 2023-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040519A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| IL263466B2 (en) | Anti-CD3 antibodies and methods of using them | |
| JP2022550851A5 (cg-RX-API-DMAC10.html) | ||
| US11191771B2 (en) | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors | |
| JP2019526595A5 (cg-RX-API-DMAC10.html) | ||
| FI3844189T3 (fi) | Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää | |
| CN115920034B (zh) | 用于治疗急性骨髓性白血病的cd70和bcl-2抑制剂的组合疗法 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP6184952B2 (ja) | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 | |
| FI3500299T3 (fi) | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa | |
| JP2018536624A5 (cg-RX-API-DMAC10.html) | ||
| RU2010123363A (ru) | Применения анти-cd40-антител | |
| JP2015517512A5 (cg-RX-API-DMAC10.html) | ||
| JP2020536932A5 (cg-RX-API-DMAC10.html) | ||
| JP2014525926A5 (cg-RX-API-DMAC10.html) | ||
| JP2019524714A5 (cg-RX-API-DMAC10.html) | ||
| AU2012296907A1 (en) | Combination therapy with an anti - CD19 antibody and a nitrogen mustard | |
| JP2015517511A5 (cg-RX-API-DMAC10.html) | ||
| JP2021523158A5 (cg-RX-API-DMAC10.html) | ||
| JP2023520771A5 (cg-RX-API-DMAC10.html) | ||
| JP2015516980A5 (cg-RX-API-DMAC10.html) | ||
| CN111225670A (zh) | 抑制Polo样激酶4的组合疗法 | |
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| JP2023500480A5 (cg-RX-API-DMAC10.html) | ||
| JP2023506779A5 (cg-RX-API-DMAC10.html) |